Onxeo Announces Establishment of U.S. Subsidiary

Pharmaceutical and biotech industry veteran, Philippe Maitre, to head U.S
subsidiary
PARIS & COPENHAGEN, Denmark--(BUSINESS WIRE (http://www.businesswire.com/))--
Regulatory News:

Onxeo S.A. (Paris:ONXEO) (NASDAQ OMX:ONXEO), an innovative company specializing
in the development of orphan oncology therapeutics, today announced the creation
of a U.S. subsidiary, based in New York City. The company also announced that
experienced industry executive Philippe Maitre will head the U.S. subsidiary
with the title of Executive VP & Chief of U.S. Operations. The U.S. subsidiary,
to be named Onxeo US, will provide services to Onxeo as the company expands its
development programs and establishes closer ties with the scientific and
financial communities in the U.S.

Judith Greciet, CEO of Onxeo, commented: “The opening of a U.S. subsidiary, to
be based in the key business, financial and medical hub of New York City, is a
significant step and an important strategic initiative aimed at achieving our
goal of connecting with more patients, physicians, Pharma and Biotech companies
and investors in the United States. Having a dedicated and experienced team
there will allow us to adapt our future activities to the needs of the largest
healthcare market in the world. We are delighted to welcome Philippe Maitre to
our team as the head of our U.S. subsidiary. Philippe is a seasoned biotech and
pharmaceutical professional with experience leading several U.S. companies, with
particular expertise in finance, business development and mergers and
acquisitions. Philippe brings a wealth of valuable industry experience to Onxeo,
and will be responsible for establishing the US subsidiary and assisting with a
series of strategic initiatives to serve Onxeo’s growth. We look forward to
working closely with him to achieve our global objectives.”

Philippe Maitre commented: “It is a privilege to join Onxeo and to work with
such a highly qualified team. Through compelling technologies and a strong
product pipeline targeting orphan diseases, including the recent acquisition of
DNA Therapeutics, there is significant potential to capitalize on numerous
research and business opportunities in the U.S. I look forward to leading the
U.S. operations and providing the input needed to advance the strategic
development of the Company.”

Mr. Maitre brings more than 35 years of experience in the pharmaceutical and
biotech industry, including nearly 15 years as Corporate Officer for US public
companies. Mr. Maitre has served as Chief Executive Officer and Co-Founder of
mAbRx, a biotech company developing monoclonal antibodies against cancer stem
cells in partnership with the Duke Cancer Center. Prior to founding mAbRx,
Philippe has been the Chief Executive Officer at Anosys, a cancer vaccine
company spin-off from Aventis (today Sanofi). He has also served as a Chief
Financial Officer for NASDAQ-listed companies Pharmaceutical Product Development
Inc. (PPD Inc.) and Oscient Pharmaceuticals. Earlier in his career, Mr. Maitre
served in various roles such as finance, business development and investor
relations at companies Rhone Poulenc, Rhone Poulenc Rorer as well as Aventis,
where he ultimately held the position of Senior Partner and Deputy CFO for
Aventis Pharma Group.

Prior to joining the Pharma Industry, Mr. Maitre served in the French Ministry
of Foreign Affairs where he was stationed in Libya. He earned his master's in
Finance from the Hautes Etudes de Commerce (HEC) Business School in Paris.

About Onxeo
Onxeo is a leading developer of orphan oncology drugs. The Company is focused on
developing innovative therapeutics for rare cancers, one of the fastest growing
markets in the healthcare industry with high, unmet medical needs. Onxeo’s
comprehensive portfolio features a broad orphan oncology pipeline, with three
independent programs in advanced clinical development, including Onxeo’s first
approved orphan oncology drug, Beleodaq®. In addition, Onxeo has successfully
developed and registered two non-cancer products which are currently being
commercialized in the U.S. and Europe. Onxeo’s vision is to become a global
leader and pioneer in oncology, with a focus on orphan or rare cancers, by
developing advanced, effective, and safe therapeutics designed to improve the
lives of patients. The Company is headquartered in Paris, France and has
approximately 50 employees. Onxeo is listed on Euronext in Paris, France
(Ticker: ONXEO, ISIN Code: FR0010095596) and Nasdaq Copenhagen, Denmark (Ticker:
ONXEO).

Onxeo orphan oncology products at the advanced development stage are:

  · Livatag® (Doxorubicin Transdrug™): Currently being evaluated in a Phase III
trial (ReLive) in patients with hepatocellular carcinoma (primary liver cancer);
and in combination with other cancer agents in first-line HCC
  · Beleodaq® (belinostat): FDA-approved in the U.S. in 2014 under the agency’s
accelerated approval program as a second-line treatment for patients with
peripheral T-cell lymphoma (PTCL) and currently marketed by Onxeo’s partner in
the U.S., Spectrum Pharmaceuticals; belinostat in combination with other cancer
agents is currently in development in first-line treatment for patients with
PTCL (BelCHOP) and in other solid tumors
  · Validive® (Clonidine Lauriad®): Positive final results from a Phase II trial
in head and neck cancer patients with severe oral mucositis;

In addition, Onxeo recently reached an agreement to acquire DNA Therapeutics, a
privately-held, clinical-stage biopharmaceutical company, for its first-in
-class, signal-interfering DNA (siDNA) repair technology, which is directed at
overcoming cancer resistance mechanisms. The transaction is expected to close by
the end of March 2016.

Learn more by
visiting www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%
3 
A%2F%2Fwww.onxeo.com&esheet=51303590&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=1&md5=d7441017c1305ff26eba199723e36008).

To receive our press releases and newsletters, please register
on: http://www.onxeo.com/en/newsletter/ (http://cts.businesswire.com/ct/CT?id=sm
a 
rtlink&url=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&esheet=51303590&newsi
t 
emid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.onxeo.com%2Fen%2Fnewsletter%2F&index=2&md5=f9af57b37
6 
cdf8e56c50dfe76b565801)
Follow us on Twitter: @Onxeo_

Disclaimer
This communication expressly or implicitly contains certain forward-looking
statements concerning Onxeo and its business. Such statements involve certain
known and unknown risks, uncertainties and other factors, which could cause the
actual results, financial condition, performance or achievements of Onxeo to be
materially different from any future results, performance or achievements
expressed or implied by such forward-looking statements. Onxeo is providing this
communication as of this date and does not undertake to update any forward
-looking statements contained herein as a result of new information, future
events or otherwise. For a discussion of risks and uncertainties which could
cause actual results, financial condition, performance or achievements of Onxeo
to differ from those contained in the forward-looking statements, please refer
to the Risk Factors ("Facteurs de Risque") section of the 2014 Reference
Document filed with the AMF on April 14, 2015, which is available on the AMF
website (http://www.amf
-france.org (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww
. 
amf-france.org&esheet=51303590&newsitemid=0&lan=en
-US&anchor=http%3A%2F%2Fwww.amf
-france.org&index=3&md5=53456d9a1035a261f93ceabfec1973f8)) or on the company’s
website
(www.onxeo.com (http://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2F
w 
ww.onxeo.com&esheet=51303590&newsitemid=0&lan=en
-US&anchor=www.onxeo.com&index=4&md5=f3473339ce2883fe5b74c95c7a52b398)).
Contacts

Nathalie Delair-Trepo, + 33 1 45 58 76 00
Investor Relations, Onxeo
investors@onxeo.com
or
Caroline Carmagnol and Florence Portejoie – Alize RP (France)
onxeo@alizerp.com
+33 6 64 18 99 59 / +33 6 47 38 90 04
or
Kirsten Thomas / Lee Roth – The Ruth Group (U.S.)
kthomas@theruthgroup.com / lroth@theruthgroup.com
+1 508 280 6592 / +1 646 536 7012